AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04280939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: prospective randomized double-blind study of patients undergoing total hip or knee replacement, as well as partial knee replacements (medial, lateral, patellafemoral, or bilateral). All groups will be matched for age, sex, American Society of Anesthesiologists class, and type of surgery. An attempt will be made to achieve a similar proportion of THA, TKA, and partial knee replacements in each group. We will randomize patients to one group of spinal anesthesia protocole.
Study NCT03554122 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients spinal injections were performed without Shotblocker
Study NCT00460512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
Study NCT04280939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: prospective randomized double-blind study of patients undergoing total hip or knee replacement, as well as partial knee replacements (medial, lateral, patellafemoral, or bilateral). All groups will be matched for age, sex, American Society of Anesthesiologists class, and type of surgery. An attempt will be made to achieve a similar proportion of THA, TKA, and partial knee replacements in each group. We will randomize patients to one group of spinal anesthesia protocole.
Study NCT01291069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil Citrate
Description: If allocated to the treatment arm, the patient will be given tadalfil citrate, 0.8-1 mg/kg/day in 1 daily dose. Maximum dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
Study NCT01291069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a mixture of Ora-Sweet® and Ora-Plus® in a 1:1 ratio. All patients will receive drug for 20 days
Study NCT02639195 — intervention group
Intervention type: OTHER
Intervention: Treatment
Description: Retrospective chart review of patients treated with manual therapy.
Study NCT01479556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.
Study NCT01479556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mg BID p.o.
Study NCT00898742 — intervention group
Intervention type: GENETIC
Intervention: DNA and tissue microarray analysis
Description: The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
Study NCT00898742 — intervention group
Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction
Description: The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
Study NCT00898742 — intervention group
Intervention type: OTHER
Intervention: mass spectrometry
Description: The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
Study NCT01892605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music listening
Description: The treatment group listened to Mozart K.448 for eight minutes once daily before bedtime for at least six months.
Study NCT00764244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: Vitrectomy
Study NCT00764244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal triamcinolone injections
Description: Intravitreal triamcinolone injections
Study NCT00764244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: Laser photocoagulation
Study NCT04245930 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bovine Pericardial Patch in Immediate Implant Breast Reconstruction
Description: Patients will receive immediate breast implant reconstruction using Bovine Pericardial Patch
Study NCT04245930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TiLOOP® Bra Mesh in Immediate Implant Breast Reconstruction
Description: Patients will receive immediate breast implant reconstruction using TiLOOP® Bra Mesh
Study NCT04577144 — intervention group
Intervention type: OTHER
Intervention: Online survey only
Description: There are no interventions planned for this study. This is an observational study only.
Study NCT02177344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of Ipratropium bromide
Description: One puff, 4 times daily by oral inhalation
Study NCT02177344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of Ipratropium bromide
Description: One puff, 4 times daily by oral inhalation
Study NCT02177344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrovent
Description: Two puffs, 4 times daily by oral inhalation
Study NCT02177344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00824681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound Of Family Together (S.O.F.T.) Music Program
Description: Audio compact disk containing songs, music, special messages, poems from children of adults with major burns
Study NCT02256319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will receive a loading dose of 1 µg/kg in 10 min before starting the surgery. The maintenance dose will be 0.2-1 µg/kg/h for a Ramsey Sedation Score of 3-4 during the surgery´s preparation. It will be reduced to 0.2 µg/kg/h 15 min before starting the microelectrode recording for a Ramsey Sedation Score of 2. After the placement of the deep brain stimulator we will record the local field potentials activity. In addition, the subscales of rigidity, tremor and bradykinesia of the Unified Parkinson's Disease Rating Scale (UPDRS-III) score will be evaluated. Once the deep brain stimulator recording and neurologic exploration will be over patients will receive a maintenance dose 0.2-1 µg/kg/h until the end of the surgery. It will be stopped to transfer the patient to the ICU.
Study NCT00824681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Therapy Related Activities (NTRA)
Description: NTRA includes non-directed activities e.g. reading books/magazines, watching TV/movie in family lounge off the BICU, playing with toys, listening to music CDs/radio.
Study NCT02447731 — intervention group
Intervention type: DEVICE
Intervention: Induction of sound waves in lungs by sonic oscillator
Description: A device called sonic oscillator will add sonic waves to the inhaled gases while the subjects are going through 3 tests measuring the variations made in pulmonary functions induced by sound waves.
Study NCT00126048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 40mg tablet
Study NCT00126048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT03136068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Trans-abdominal injection
Study NCT03136068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Trans-abdominal injection
Study NCT01183091 — intervention group
Intervention type: PROCEDURE
Intervention: Ablation of atrial fibrillation
Description: Ablation of atrial fibrillation
Study NCT00432380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: oral doses
Study NCT00432380 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dose
Study NCT00432380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral dose
Study NCT01105533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
Study NCT02950415 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: virtual
Description: Parent is present via an internet pad (iPad)
Study NCT02950415 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: coaching
Description: Parent learns what to say verbally to soothe child
Study NCT02950415 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: physical
Description: Parent is present in the operating room
Study NCT02950415 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: no coaching
Description: Parent does not learn what to say verbally to soothe child
Study NCT03910400 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computation of quantitative flow ratio
Description: After stents were implanted whenever technically possible in the STEMI patients, the investigators created a temporary artificial stenosis inside the stent by partially inflating a balloon catheter during pharmacologic hyperemia.~Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections with the artifical stenosis, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
Study NCT01105533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 1mg Capsule Once Daily (Dose Escalation) Continuous
Study NCT01105533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 2mg Capsule Once Daily (Dose Escalation) Continuous
Study NCT01105533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 4mg Capsule Once Daily (Dose Escalation) Continuous
Study NCT01105533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 6mg Capsule Once Daily (Dose Escalation) Continuous
Study NCT01105533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 9mg Capsule Once Daily (Dose Escalation) Continuous
Study NCT01105533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 8mg Capsule Once Daily (Dose Escalation) Continuous
Study NCT01105533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 4mg Capsule Twice Daily (Dose Escalation) Continuous
Study NCT01105533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 6mg Capsule Twice Daily (Dose Escalation) Continuous
Study NCT02256319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The target doses are 0.5, 1, 1.5, 2 and 2.5 µg/kg. For its administration we will use the TCI (target controlled infusion) system. After programming each dose we will wait until the plasma and brain concentration of propofol are stabilized in this target and then we will record the local field potentials activity through the DBS. In addition, the subscales of rigidity, tremor and bradykinesia of the UPDRS-III score will be evaluated.
Study NCT03909373 — intervention group
Intervention type: OTHER
Intervention: PSFS
Description: Patients will complete the patient specific functional scale. no intervention being administered
Study NCT04457531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LiuWeiLuoBi Granule
Description: LiuWeiLuoBi Granule is a Chinese medicine made from 6 herbal medicine, including Shaji(Sea-buckthorn), Honghua (Safflower), Jinyinhua(Honeysuckle),etc.
Study NCT04457531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard medical treatment
Description: Standard medical therapy is adhered to the guidline issued by American Diabetes Association and Chinese Diabetes Society at 2017, including keeping an appropriate diet, doing some exercises, the pharmacological therapy to control the blood glucose, blood pressure and blood lipids.
Study NCT04457531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Standard medical therapy is adhered to the guidline issued by American Diabetes Association and Chinese Diabetes Society at 2017, including keeping an appropriate diet, doing some exercises, the pharmacological therapy to control the blood glucose, blood pressure and blood lipids.
Study NCT01261429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasigna
Description: The study drug is nilotinib (Tasigna®). All patients will be administered with nilotinib 400 mg twice a day for one year. The patient will begin the treatment the day of inclusion.~The prescribed dose should be swallowed whole with a glass of water. Doses of 400 mg should be administered twice daily approximately 12 hours apart. Patients should not eat within two hours before and one hour after taking nilotinib and need to avoid foods such as grapefruit juice which may inhibit CYP3A4 enzymes.
Study NCT04093479 — intervention group
Intervention type: OTHER
Intervention: blood samples
Description: blood samples will be taken repeatedly
Study NCT02173301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP23829 400 mg QD
Description: active dose 1
Study NCT02173301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP 23829 800 mg QD
Description: active dose 2
Study NCT02173301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP23829 400 mg BID
Description: active dose 3
Study NCT02173301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control
Study NCT04557982 — intervention group
Intervention type: PROCEDURE
Intervention: A painful procedure (peripheral venepuncture)
Description: The child will undergo a peripheral venepuncture during a scheduled visit to a hospital clinic and routinely provided care.
Study NCT03535506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib capsules for oral administration contain 125 mg, 100 mg, or 75 mg of palbociclib, a kinase inhibitor.
Study NCT03078530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a pill with inactive ingredients
Study NCT03078530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visbiome
Description: This is a probiotic mixture available to randomized study participants, starting with subject 29
Study NCT03078530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: This is a probiotic mixture available to the first 28 subjects randomized to the study
Study NCT02858167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: FDG injection followed by cerebral examination with X ray spiral CT after 40 minutes and FDG-PET after 60 minutes
Study NCT05785416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Stretching - Contract Relax stretching (PNF-CR)
Description: PNF-CR utilized the concept of autogenic inhibition of the muscle for improving the flexibility of the muscle. It includes stretching a muscle after a brief period of activation.
Study NCT05785416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Description: The SS technique utilized the concept of creep for improving the hamstring flexibility. The stretch was maintained for a prolonged period passively by the therapist.
Study NCT03120520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide
Study NCT03120520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Study NCT01123980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
Study NCT01123980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day.
Study NCT01123980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day.
Study NCT01123980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day.
Study NCT01123980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day.
Study NCT01123980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
Study NCT04330482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE-Well App
Description: Participants randomized into this group will be instructed to use the CARE-Well App at least 4 times per week.
Study NCT04330482 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet Links
Description: Participants randomized into this group will be instructed to use a computer tablet pre-loaded with a list of internet links relevant to dementia caregiving at least 4 times per week.
Study NCT02238470 — intervention group
Intervention type: DRUG
Intervention: oral anticoagulants
Description: Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging
Study NCT06684405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sodium sodium fluoride solution (0.75 mg for subjects aged 12 and 1.0 mg for subjects aged 13)
Study NCT06684405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Subjects in the control group received a daily dose of 0.5 ml sterile water to be added to 200 ml of milk.
Study NCT03443180 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gluten and Amylase Trypsin Inhibitors (ATI)-free diet
Description: Participants will be asked to avoid foods containing gluten and ATI (a similar protein found in grains) for 4 weeks.
Study NCT03976843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: 18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
Study NCT03739996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Cabotegravir (CAB)
Description: 30 mg tablets administered orally
Study NCT03739996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Description: NRTIs will not be provided by the study. Participants will obtain NRTIs outside of the study through routine care.
Study NCT03739996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-Acting Injectable Cabotegravir (CAB LA)
Description: 600 mg loading dose followed by 400 mg maintenance doses administered by intramuscular (IM) injection
Study NCT03739996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: 40 mg/kg administered as an intravenous (IV) infusion
Study NCT03739996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) Oral ART
Description: SOC ART will not be provided by the study. Participants will obtain SOC ART outside of the study through routine care.
Study NCT03848000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Programme
Description: Two sessions per week for 12 consecutive weeks. 30 minute education talks covering topics regarding the physical and mental health benefits of exercise and behaviour change. The following 30-60 minute exercise sessions will utilise pad-boxing, football, body-weight training and circuit training.
Study NCT03848000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NHS Standard Care
Description: Weekly one-to-one cognitive-behavioral counselling alcohol addiction support session lasting 1 hour. Drug therapy will be offered if indicated in line with standard therapy.
Study NCT03848000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NHS Standard Care
Description: Weekly one-to-one cognitive-behavioral counselling alcohol addiction support session lasting 1 hour. Drug therapy will be offered if indicated in line with standard therapy.
Study NCT01105533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00337210
Description: 6mg Capsule Twice Daily (Dose Expansion) Continuous
Study NCT01698060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ND1.1
Study NCT02106793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomicin C
Description: Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
Study NCT02066298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone 220mcg BID
Description: Mometasone is an ICS
Study NCT03856294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rikkunshito
Description: Rikkunshito, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake